CTIS2022-502288-40-00进行中（未招募）1 期
A Phase 1/Phase 2 Study to Evaluate the Safety and Tolerability of MK-1088 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumors - MK-1088-002
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 95
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Has a histologically- or cytologically-confirmed diagnosis of advanced/metastatic solid tumor by pathology report and have received, have been intolerant to, or have been ineligible for treatment known to confer clinical benefit, For metastatic castrate-resistant prostate cancer (mCRPC) only: (1) Must have previously received docetaxel, prior treatment with one other chemotherapy is allowed as well as up to 2 second-generation hormonal manipulations and (2) have prostate cancer progression within 6 months before screening, as determined by the investigator, If human immunodeficiency virus (HIV) positive, has well-controlled HIV on anti-retroviral therapy (ART)
排除标准
- •Has had chemotherapy, definitive radiation, or biological cancer therapy within 4 weeks (2 weeks for palliative radiation) before the first dose of study intervention, Has not fully recovered from any effects of major surgery without significant detectable infection, Has a history or current evidence of a gastrointestinal (GI) condition or impaired liver function or diseases that in the opinion of the investigator may significantly alter the absorption or metabolism of oral medications, Has clinically significant cardiovascular disease within 12 months from first dose of study intervention, including NYHA Class III or IV congestive heart failure, unstable angina, myocardial infarction, cerebral vascular accident, or cardiac arrhythmia associated with hemodynamic instability, Has a QTcF >470 msec, Has history of an allogeneic stem cell transplant or a solid organ transplant, Has received prior systemic anticancer therapy including investigational agents within 4 weeks before allocation, Has received prior radiotherapy within 2 weeks of start of study intervention, or had radiation-related toxicities requiring corticosteroids, Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention, Has a superscan bone scan, Has a history of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 2 years, Has clinically active central nervous system (CNS) metastases and/or carcinomatous meningitis, Has an active infection requiring therapy, Has a history of interstitial lung disease, Has a history of (noninfectious) pneumonitis that required steroids or current pneumonitis, Has an active autoimmune disease that has required systemic treatment in the past 2 years, Has concurrent active Hepatitis B and Hepatitis C virus infection, Has HIV with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
研究者
相似试验
进行中（未招募）
1 期
A Phase 1/Phase 2 Study to Evaluate the Safety and Tolerability of MK-1088 as Monotherapy/ single agent and in Combination with Pembrolizumab in Participants with Advanced Solid TumorsEUCTR2021-006712-93-DKMerck Sharp & Dohme LLC80
进行中（未招募）
1 期
aEUCTR2019-004883-23-FRAPHP
进行中（未招募）
1 期
HTLPSCID pediatric patients (n=12 for analysis) requiring an HLA partially compatible allogeneic HSCT.MedDRA version: 20.0Level: PTClassification code 10010099Term: Combined immunodeficiencySystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2018-001029-14-FRASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)12
进行中（未招募）
1 期
study to investigate the safety and clinical activity of APR-246 in combination with dabrafenib in patients with unresectable metastatic melanoma resistant to dabrafenib /trametinib combinatioEUCTR2017-002577-18-BEAPREA THERAPEUTICS AB50
进行中（未招募）
1 期
Safety and Efficacy of AMG 592 in Subjects with Active Rheumatoid ArthritisMedDRA version: 20.0Level: HLTClassification code 10039075Term: Rheumatoid arthritis and associated conditionsSystem Organ Class: 100000004870Rheumatoid ArthritisEUCTR2017-001944-36-BGAmgen Inc153